Avisa Pharma Inc
We have developed the first, rapid, point of care test for pneumonia that provides for appropriate use of antibiotics to combat antibiotic resistant infections
Avisa is a venture-backed company developing and commercializing the first rapid, point-of-care breath test for the diagnosis of pulmonary infections.
The rise of antibiotic resistant infections costs the U.S. healthcare system over $20 billion each year. We are seeking $1,000,000 of a $3,000,000 Convertible Note financing of which $2,000,000 has been invested by current shareholders for runway expansion for $15 million Series B round underway.